Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  Khavinson Peptide Bioregulators (class entry)
Research reference — not for sale

Khavinson Peptide Bioregulators (class entry)

F
lead outcome
Class-level: independent replication of any…
grades vary by outcome ↓
Peptide
also called — peptide bioregulators · short peptide bioregulators · cytogens (synthetic) · cytomedins / cytamins (tissue extracts) · Хавинсоновские пептидные биорегуляторы · Vilon, Vesugen, Livagen, Pancragen, Chonluten, Cardiogen, Bronchogen, Testagen, Prostamax, Crystagen, Ovagen, Thymagen, Cartalax and others
peptide bioregulator classgene expression (proposed)geroprotection (claimed)tissue-specific signalling (proposed)

Status: class reference entry — not for sale. No dosing, reconstitution, or administration is published (intentional). Neutral scientific reference only. Note that circulating dose protocols for these compounds are community conventions with no human trial basis, and that for several products the sequence sold is not consistent between suppliers.

In brief

The Khavinson peptide bioregulators are a family of very short peptides — typically two to four amino acids — developed since the 1970s at the St Petersburg Institute of Bioregulation and Gerontology, on the premise that each organ produces characteristic short peptides that regulate its gene expression, that these decline with age, and that supplying them slows ageing. The catalogue now runs to dozens of products, one per organ: Vilon (thymus), Cortagen (cortex), Pinealon (brain), Cartalax (cartilage), Cardiogen (heart), Vesugen (vessels), Pancragen (pancreas), Livagen (liver), Chonluten (lung), Testagen, Prostamax, Crystagen, Ovagen and more, each paired with a corresponding tissue extract. This entry exists because the class shares one evidence structure and three problems that recur identically in every member. First, essentially nothing has been independently replicated — forty-plus years of output from a single institute, roughly half in untranslated Russian. Second, human clinical credibility belongs to the extracts (Cortexin and thymalin are registered medicines in Russia), not to the synthetic peptides sold on it; and where extract and peptide were compared, they diverged. Third, for several products the sellers themselves disagree on the amino acid sequence — Cartalax is described variously as AED, AEDL, AEDG and Ala-Glu — so what is in the vial cannot be established. The underlying mechanism claim, that a di- or tetrapeptide binds DNA sequence-specifically to control organ-specific transcription, remains extraordinary and unconfirmed outside the originating group. Individual entries exist for epitalon, epithalamin, pinealon and cortagen; this entry covers the class and the members without separate coverage.

Legal standing, by region
European Union
Not approved

No bioregulator holds marketing authorisation as a medicine in the EU, and none is an authorised novel food or cosmetic ingredient. Animal-tissue-derived cytamins face additional regulatory scrutiny. Sold as research chemicals or unregistered supplements, neither of which authorises human use.

United Kingdom
Not approved

No marketing authorisations; research chemical status.

United States · your region
Not FDA-approved

No FDA approval for any indication for any member. Bovine-derived tissue extracts (e.g. epithalamin) are categorically ineligible as bulk drug substances for 503A compounding — not components of approved drugs, no USP/NF monograph, not on the FDA bulk substances list. Synthetic peptides are sold "for research use only".

International
Some extracts registered in Russia; synthetics not approved in the West

**Cortexin** (cortical extract) and **thymalin** (thymic extract) are registered medicines in Russia and several former Soviet states with decades of clinical use. That registration applies to those extracts only. It does not extend to the synthetic peptides derived from them, and Russian registration does not correspond to EMA or FDA evidentiary standards.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Class-level: independent replication of any bioregulator claim
This single fact governs the entire category. Forty-plus years of internally consistent output from one institute, much of it inaccessible to outside review, is a distinct and weaker kind of evidence than replicated science — regardless of paper count.
Across the class, published work traces overwhelmingly to Vladimir Khavinson's programme at the St Petersburg Institute of Bioregulation and Gerontology and its collaborators. The Alzheimer's Drug Discovery Foundation's review of the programme's flagship compounds (epithalamin and epitalon) states directly that every preclinical and clinical study was conducted by Khavinson's group with no independent confirmation, and that roughly half of the ~110 papers are in Russian without English translation. Independent commentary in practitioner forums reaches the same conclusion for the wider class. · No claim in this class has been independently reproduced by an unaffiliated group.
F
Class-level: human clinical evidence for the synthetic peptides
Where human clinical claims are made, they nearly always belong to the **tissue extracts**, not the synthetic peptides — see the substitution problem below. The synthetic compounds are sold individually for human use on evidence that does not concern them.
No synthetic bioregulator peptide (Cortagen, Pinealon, Cartalax, Vilon, Vesugen, Livagen, Pancragen, Cardiogen, Bronchogen, Chonluten, Testagen, Prostamax, Crystagen, Ovagen and the rest) has a published or registered human efficacy trial, pharmacokinetic study or safety dataset. · Nothing demonstrated in humans for any synthetic member.
F
The extract-for-peptide substitution (structural problem)
This is not a semantic quibble. Extracts contain dozens of peptides in variable ratios; a single tetrapeptide is a different substance. Where the two have been compared directly, they have **diverged** — epitalon failed to stimulate melatonin in rats (Djeridane et al., 2003) while epithalamin reportedly did. The programme's own data therefore contradict the assumption that the peptide carries the extract's activity.
The programme systematically pairs a crude animal-tissue extract with a synthetic short peptide derived from its amino acid analysis: **epithalamin → epitalon**, **Cortexin → Cortagen**, and across the catalogue **cytamins** (Suprefort/pancreas, Ventfort/vessels, Endoluten/pineal, Svetinorm/liver, Sigumir/cartilage and others) paired with **cytogens** (Pancragen, Vesugen, Epitalon and others). Clinical familiarity — including genuine registered medical use in Russia for Cortexin and thymalin — belongs to the extract side. · Evidence earned by mixtures is routinely presented as evidence for defined synthetic peptides.
F
Compound identity and sequence consistency (as sold)
When the people selling a compound cannot agree on its amino acid sequence, no evidence claim about it can be evaluated — and a buyer cannot know what is in the vial. This is the most practically important finding about the class and it is independent of any judgement about the underlying science.
Vendor and secondary sources disagree on the basic structure of individual bioregulators. **Cartalax** is variously described as the tripeptide Ala-Glu-Asp (AED), the tetrapeptide Ala-Glu-Asp-Lys, the tetrapeptide Ala-Glu-Asp-Gly (AEDG — which is actually epitalon's sequence), and even the dipeptide Ala-Glu. **Cortagen** is generally AEDP but at least one source describes it as supporting "cortisol levels and adrenal gland function" — conflating cerebral *cortex* with adrenal *cortex*. Circulating dose conventions differ by an order of magnitude between sources for the same product. · For several members of the class, there is no consistent account of what the substance actually is.
F
Class mechanism: short peptides as sequence-specific gene regulators
The measurements do not establish the claim. Demonstrating that a peptide changes *some* transcription *somewhere* is far weaker than organ-addressed transcriptional control. And the specificity claim is biophysically demanding: sequence-specific DNA recognition is normally achieved by structured protein domains far larger than two to four residues, which carry correspondingly more information. A dipeptide such as Vilon (Lys-Glu) specifying a thymus-specific genomic address is an extraordinary proposition. Note also that several members share the same **AED core** (epitalon AEDG, bronchogen AEDL, cardiogen AEDR, cartalax AED), with organ specificity attributed to a single terminal residue.
The framework holds that peptides of two to four residues cross the plasma membrane and nuclear envelope without receptor mediation, bind DNA and histone proteins directly at promoter regions, and thereby restore tissue-specific gene expression — each peptide addressed to its own organ. Supporting work includes nuclear-penetration imaging with fluorescence-labelled peptides and in vitro oligonucleotide binding (Fedoreyeva, Kireev, Khavinson, Vanyushin), microarray gene expression changes (Anisimov et al., 2004), IL-2 expression in splenocytes (Kazakova et al., 2002), and IGF1 upregulation in aging human mesenchymal stem cells (Ashapkin et al., 2020). · Real measurements exist showing that short peptides can enter nuclei, bind oligonucleotides in vitro, and alter some gene expression.
D
Preclinical signals (animal and cell)
Consistency across a catalogue produced by one programme is ambiguous evidence: it may indicate a real class effect, or a consistent methodology and interpretation. Rodent lifespan claims of 20-40% exceed what caloric restriction achieves in many strains — magnitudes that make independent replication essential rather than optional. Several studies also test **combinations** (Pinealon with Cortexin; thymalin with epithalamin), preventing attribution to single compounds, and neuroprotection work has typically used pretreatment rather than post-injury designs.
Across the class: reported lifespan extension of 20-40% in rodents and Drosophila (Anisimov & Khavinson, Biogerontology 2010), reduced ROS and apoptosis in neuronal cultures (Pinealon), chondrocyte proliferation and matrix gene expression (Cartalax), sciatic nerve regeneration and cortical explant growth (Cortagen), telomerase activity in human somatic cells in vitro (epitalon), and IGF1 upregulation in senescent stem cells (AED). · Directionally consistent preclinical activity reported across many tissues and compounds.
C
Human safety
Two distinct risk profiles sit inside one category. The **synthetic peptides** are short chains of common dietary amino acids, which is often taken as reassurance — reasonable inference, but not data. The **tissue extracts** (cytamins) are animal-derived preparations of variable composition, carrying immunogenicity considerations and, for bovine-derived material, the regulatory legacy of transmissible spongiform encephalopathy concerns. Circulating dose protocols (commonly 200-400 mcg for 10-20 days, or 10-20 mg orally) are community conventions with no trial basis — a point some vendor sources concede outright.
No independent human safety characterisation for any synthetic member of the class. The originating programme reports long-term administration without notable adverse events. · Not established.
—
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Khavinson Peptide Bioregulators (class entry) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Identity

The Khavinson peptide bioregulators are not one substance but a product class — several dozen preparations developed from the 1970s onward at the St Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, on a single organising hypothesis.

That hypothesis: every tissue produces characteristic ultrashort peptides (two to four residues) that act as regulatory signals for that tissue's gene expression; their production declines with age; and supplying them exogenously restores youthful expression patterns. Each organ therefore gets its own peptide.

The class divides into two physically different kinds of product, and the distinction matters more than any other fact about it:

  • Cytomedins / cytamins — crude peptide extracts from animal tissue. Examples: Cortexin (bovine/porcine cerebral cortex), epithalamin (bovine pineal), thymalin (thymus), Suprefort (pancreas), Ventfort (vessels), Endoluten (pineal), Svetinorm (liver), Sigumir (cartilage). Mixtures of dozens of peptides in variable ratios.
  • Cytogens — defined synthetic short peptides derived from amino acid analysis of those extracts. Examples: epitalon (AEDG), Cortagen (AEDP), Pinealon (EDR), Vilon (Lys-Glu), Vesugen (KED), Livagen (KEDA), Pancragen (KEDW), Chonluten (EDG), Cardiogen (AEDR), Bronchogen (AEDL), Cartalax, Testagen, Prostamax, Crystagen, Ovagen, Thymagen.

Vallydia carries separate entries for epitalon, epithalamin, pinealon and cortagen. This entry covers the class and the many members that have no independent evidence base of their own.

Development & history

  • 1970s: Khavinson and V. G. Morozov begin the programme with tissue extracts, starting from thymic and pineal preparations. Thymalin and epithalamin emerge as the founding cytomedins.
  • 1980s-1990s: Extensive animal work reported — lifespan extension in rats, mice and Drosophila; melatonin, immune and endocrine effects. Cortexin enters Russian clinical practice as a registered neurological medicine.
  • 2000s: The shift to cytogens — defined synthetic peptides derived from the extracts. Epitalon (from epithalamin) and Cortagen (from Cortexin) are the paradigm cases. Mechanistic work turns to gene expression: microarray studies, IL-2 expression in splenocytes, nuclear penetration of labelled peptides.
  • 2003: The programme's central human claim — a 6-to-8-year follow-up of 266 elderly subjects on thymalin and epithalamin reporting 2-to-4-fold lower mortality (unrandomised, unblinded, combination treatment).
  • 2010: Anisimov and Khavinson summarise 20-40% lifespan extension across the class (Biogerontology).
  • 2010s-2020s: The catalogue expands to cover essentially every organ system, and the compounds enter Western supplement and research-chemical markets, sold individually and in "protocol" stacks.
  • Throughout: no replication by any unaffiliated research group has been identified, for any member.

Mechanism (as proposed)

The class mechanism is uniform and is what distinguishes these compounds from conventional peptide drugs. Ordinary peptide therapeutics bind cell-surface receptors; bioregulators are proposed to be small enough to cross the plasma membrane and nuclear envelope unaided, then bind DNA and histone proteins directly in promoter regions, modulating chromatin and transcription. Organ specificity is attributed to cognate binding motifs in tissue-specific promoters — so EDR addresses neural tissue, AEDG the pineal, AEDP the cortex, AEDL bronchial tissue, AEDR cardiac tissue, and so on.

Supporting evidence exists and should be stated fairly: fluorescence-labelled short peptides have been imaged entering nuclei; short peptides bind deoxyribooligonucleotides in vitro; microarray studies show altered expression profiles after exposure; the AED peptide raised IGF1 expression several-fold in senescent human mesenchymal stem cells.

The gap between that evidence and the claim is the issue. Showing that a peptide enters a nucleus, binds DNA in a tube, and changes some transcription somewhere does not establish organ-addressed regulatory control. And the specificity proposition is biophysically hard: DNA sequence recognition normally requires structured domains an order of magnitude larger, because a two-to-four residue peptide simply carries very little information with which to specify a genomic address. Notably, several members share an identical AED core, with organ specificity resting on a single terminal residue — a very fine distinction to carry an entire tissue-targeting theory.

Reading the evidence honestly

Four observations, which apply to every compound in the class.

Nothing has been independently replicated. This is stated plainly by the ADDF's reviewers for the flagship compounds and holds across the catalogue. Forty years of consistent findings from one institute, with roughly half the literature untranslated, is not the same as forty years of accumulated science. Consistency within a programme measures the programme, not the world.

The clinical credibility belongs to the extracts, not the peptides being sold. Cortexin and thymalin are genuinely registered medicines in Russia with decades of clinical use. Cortagen, Pinealon, Cartalax and the rest of the synthetic catalogue have no human trials at all. Every time a source says "decades of Russian clinical use," check which substance it means — it is almost always the extract. And the programme's own data show the two can diverge: epitalon failed to reproduce epithalamin's melatonin effect in rats.

For several products, the sellers disagree about what the molecule is. Cartalax appears in vendor and secondary sources as AED (tripeptide), Ala-Glu-Asp-Lys, AEDG (which is epitalon's sequence), and Ala-Glu (dipeptide). Cortagen is usually AEDP but at least one source describes it as an adrenal-cortex compound for cortisol, confusing two unrelated organs. Dose conventions differ tenfold between sources for the same product. When basic identity is unsettled among suppliers, no evidence claim can be checked and no buyer can know what they have.

The class structure itself invites scepticism. One short peptide per organ, each with a dedicated genomic address, generating an indefinitely extensible catalogue of products — this is unusually tidy for biology and unusually convenient commercially. That is not a refutation; symmetry is not proof of error. But it does mean the burden of evidence should be higher than for a single compound, and it is currently lower.

None of this establishes that the underlying idea is wrong. Age-related decline in tissue-specific signalling is real; short peptides do have biological activity; the AED/IGF1 stem-cell result is a genuine measurement. The grade reflects the state of the evidence — unreplicated, human-untested for the synthetics, and in several cases attached to compounds of unsettled identity — not a verdict on the hypothesis.

Sources — 9 cited
01Khavinson VKh. Peptides and ageing. Neuroendocrinol Lett. 2002 (foundational monograph for the bioregulator framework).
02Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010.
03Khavinson VKh, Kuznik BI. Peptide Bioregulators (monograph). 2014.
04Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuroendocrinol Lett. 2004;25(1-2):87-93.
05Kazakova TB, et al. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. Bull Exp Biol Med. 2002;133:614-616.
06Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc).
07Ashapkin V, et al. (2020) — AED peptide and IGF1 expression in aging human mesenchymal stem cells.
08Djeridane Y, et al. (2003) — epitalon failed to stimulate melatonin production in rats (extract/peptide divergence).
09Alzheimer's Drug Discovery Foundation, Cognitive Vitality: Epithalamin and Epithalon — independent review noting absence of external confirmation and untranslated literature.
Updated 2026-07-22 (the class-defining question is unchanged since the 1990s — whether any unaffiliated group replicates any bioregulator finding; re-check for non-Khavinson primary studies)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Epitalon (Epithalon)C
Peptide
EpithalaminF
Peptide
Pinealon (EDR)F
Peptide
Cortagen (AEDP)F
Peptide
ThymalinC
Peptide
Explore by goal
Longevity & cellular →Sleep & circadian →Neuro & cognitive →Immune & thymic →
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen data
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Khavinson peptide bioregulators — class evidence & regulatory status · Vallydia